Interaction and medical inducement between pharmaceutical representatives and physicians: A meta-synthesis

Journal of Pharmaceutical Policy and Practice

Volumn 9, Issue 1, 2016, Pages

  Salmasi, Shahrzad ^a   Ming, Long Chiau ^b   Khan, Tahir Mehmood ^c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TASMANIA   (Australia)

^c MONASH UNIVERSITY MALAYSIA   (Malaysia)

^d Abasyn University   (Pakistan)

Author keywords

Health care quality; Inducement; Marketing ethics; Motivation; Pharmaceutical marketing; Pharmaceutical representatives; Prescription behavior

Indexed keywords

CONTENT ANALYSIS; CONTROLLED STUDY; DATA EXTRACTION; DOCTOR PATIENT RELATION; DRUG SYNTHESIS; ETHICS; GERMANY; HUMAN; HUMAN EXPERIMENT; INDIA; JAPAN; LIBYAN ARAB JAMAHIRIYA; MARKETING; MEDLINE; MOTIVATION; PERCEPTION; PERU; PRACTICE GUIDELINE; PRESCRIPTION; QUANTITATIVE STUDY; TURKEY (REPUBLIC); UNITED KINGDOM; UNITED STATES; YEMEN;

EID: 84998996032     PISSN: None     EISSN: 20523211     Source Type: Journal    
DOI: 10.1186/s40545-016-0089-z     Document Type: Review

References (44)

1. WHO. Trade, foreign policy, diplomacy and health. 2014. Available online: http://www.who.int/trade/glossary/story073/en/. Accessed 10 Aug 2014.
2. Othman N, Vitry AI, Roughead EE, Ismail SB, Omar K. Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia. BMC Public Health. 2010;10:743.
3. Spurling GK, Mansfield PR, Montgomery BD, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med. 2010;7:e1000352.
4. IMS Health. Global Pharmaceuticals Marketing Channel Reference. 2015. Available from: Global Pharmaceuticals Marketing Channel Reference. Accessed 24 Apr 2016.
5. Gagnon MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 2008;5:e1.
6. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006;295:429-33.
7. Stark TJ, Brownell AK, Brager NP, Berg A, Balderston R, Lockyer JM. Exploring Perceptions of Early-Career Psychiatrists About Their Relationships With the Pharmaceutical Industry. Acad Psychiatry. 2015;40:249-54.
8. Stark T. Interactions between physicians and the pharmaceutical industry: A study into the perceptions of the early career psychiatrist. Canada: University of Calgary; 2014.
9. De Ferrari A, Gentille C, Davalos L, Huayanay L, Malaga G. Attitudes and relationship between physicians and the pharmaceutical industry in a public general hospital in Lima, Peru. PloS One. 2014;9:e100114.
10. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004;351:1885-90.
11. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373-80.
12. Edwards DA. Gifts to physicians from the pharmaceutical industry. JAMA. 2000;283:2656. author reply 7-8.
13. Howard SM. Gifts to physicians from the pharmaceutical industry. JAMA. 2000;283:2655-6. author reply 7-8.
14. McKinney WP, Rich EC. Gifts to physicians from the pharmaceutical industry. JAMA. 2000;283:2656-7. author reply 7-8.
15. Tenery Jr RM. Gifts to physicians from the pharmaceutical industry. JAMA. 2000;283:2655-8.
16. Tenery Jr RM. Interactions between physicians and the health care technology industry. JAMA. 2000;283:391-3.
17. Vollmann J. Gifts to physicians from the pharmaceutical industry. JAMA. 2000;283:2656. author reply 7-8.
18. Liesegang TJ. Physicians and the pharmaceutical industry: is a gift ever just a gift? Wazana A. JAMA 2000;283:373-380. Am J Ophthalmol. 2000;130:261.
19. Green J, Thorogood N. Chapter 10 Reading, Appraising and Integrating Qualitative Research. In: Qualitative Methods for Health Research. London: Sage, 2013.
20. Walsh D, Downe S. Meta-synthesis method for qualitative research: a literature review. J Adv Nurs. 2005;50:204-11.
21. Al-Areefi MA, Hassali MA, Ibrahim MI. Physicians' perceptions of medical representative visits in Yemen: a qualitative study. BMC Health Serv Res. 2013;13:331.
22. Alssageer MA, Kowalski SR. A survey of pharmaceutical company representative interactions with doctors in Libya. Libyan J Med. 2012;7:18556. http://dx.doi.org/10.3402/ljm.v7i0.18556.
23. Brett AS, Burr W, Moloo J. Are gifts from pharmaceutical companies ethically problematic? A survey of physicians. Arch Intern Med. 2003;163:2213-8.
24. Misra S, Ganzini L, Keepers G. Psychiatric resident and faculty views on and interactions with the pharmaceutical industry. Acad Psychiatry. 2010;34:102-8.
25. Morgan MA, Dana J, Loewenstein G, Zinberg S, Schulkin J. Interactions of doctors with the pharmaceutical industry. J Med Ethics. 2006;32:559-63.
26. Saito S, Mukohara K, Bito S. Japanese practicing physicians' relationships with pharmaceutical representatives: a national survey. PLoS One. 2010;5:e12193.
27. Wang Y, Adelman RA. A study of interactions between pharmaceutical representatives and ophthalmology trainees. Am J Ophthalmol. 2009;148:619-22.e3.
28. Anderson BL, Silverman GK, Loewenstein GF, Zinberg S, Schulkin J. Factors associated with physicians' reliance on pharmaceutical sales representatives. Acad Med. 2009;84:994-1002.
29. Lieb K, Brandtönies S. A survey of German physicians in private practice about contacts with pharmaceutical sales representatives. Dtsch Arztebl Int. 2010;107:392-8.
30. Roy N, Madhiwalla N, Pai SA. Drug promotional practices in Mumbai: a qualitative study. Indian J Med Ethics. 2007;4:57-61.
31. Alssageer MA, Kowalski SR. What do Libyan doctors perceive as the benefits, ethical issues and influences of their interactions with pharmaceutical company representatives? Pan Afr Med J. 2013;14:132.
32. Sarikaya O, Civaner M, Vatansever K. Exposure of medical students to pharmaceutical marketing in primary care settings: frequent and influential. Adv Health Sci Educ. 2009;14:713-24.
33. Prosser H, Walley T. Understanding why GPs see pharmaceutical representatives: a qualitative interview study. Br J Gen Pract. 2003;53:305-11.
34. Fischer MA, Keough ME, Baril JL, et al. Prescribers and pharmaceutical representatives: why are we still meeting? J Gen Intern Med. 2009;24:795-801.
35. Mintzes B, Mangin D, Hayes L and Organization WH. Understanding and responding to pharmaceutical promotion: a practical guide. World Health Organization; 2009. Available from: http://haiweb.org/wp-content/uploads/2015/05/Pharma-Promotion-Guide-English.pdf. Accessed 2 May 2016.
36. World Health Organization/Health Action International. Understanding and responding to pharmaceutical promotion- a practical guideline. 2010. Available from: http://www1.paho.org/hq/dmdocuments/2011/drugpromotion-manual-CAP-3-090610.pdf. Accessed 10 June 2016.
37. Theodorou M, Tsiantou V, Pavlakis A, et al. Factors influencing prescribing behaviour of physicians in Greece and Cyprus: results from a questionnaire based survey. BMC Health Serv Res. 2009;9:150.
38. Cialdini RB. Influence: Science and practice. 2009.
39. World Health Organisation. Ethical criteria for medicinal drug promotion. Geneva: WHO; 1988. Available from: http://apps.who.int/medicinedocs/documents/whozip08e/whozip08e.pdf. Accessed 10 Jun 2015.
40. McGettigan P, Golden J, Fryer J, Chan R, Feely J. Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message. Br J Clin Pharmacol. 2001;51:184-9.
41. Vinson DC, McCandless B, Hosokawa MC. Medical students' attitudes toward pharmaceutical marketing: possibilities for change. Fam Med. 1993;25:31-3.
42. King M, Essick C, Bearman P, Ross JS. Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis. BMJ. 2013;346:f264.
43. Epstein AJ, Busch SH, Busch AB, Asch DA, Barry CL. Does exposure to conflict of interest policies in psychiatry residency affect antidepressant prescribing? Med Care. 2013;51:199-203.
44. McCormick BB, Tomlinson G, Brill-Edwards P, Detsky AS. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA. 2001;286:1994-9.